Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Vir Biotechnology, Inc.NASDAQ: VIR

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 147.36M shares rose 7.2% year over year, ahead of the +3.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +7.2% holds above the trailing-twelve-month pace of +3.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
147.36M+5.8% QoQ
Last fiscal yearDec 2025
138.52M+1.7% YoY
LTMMar 2026
140.99M+3.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.2%——
1 year+1.7%——
3-year CAGR+1.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
138.52M USD
Year-over-year change
+1.7%
4-year CAGR
+1.6%

Weighted Avg Shares vs competitors

How VIR compares with its peers on the latest reported figures

  • VIR's LTM Mar 2026 weighted avg shares of 140.99M shares is the 6th highest of the 10 companies compared; the peer median is 162.41M shares.
  • Its year-over-year change of +3.1% is the 5th highest of 10, against a peer median of +3.0%.
  • Over three fiscal years its annual growth of +1.5% compares with a peer median of +4.1%.
VIR Competitors Peer median
Weighted Avg Shares for VIR and competitors
Company Period LTM YoY 3-year CAGR
MRNAModerna, Inc.LTM Sep 2026396M +2.3%-0.4%
BNTXBioNTech SELTM Jun 2026247.64M +3.0%-0.2%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026229.47M +10.2%+4.1%
ABUSArbutus Biopharma CorporationLTM Mar 2026192.17M +2.0%+8.3%
NVAXNovavax, Inc.LTM Mar 2026162.41M +3.2%+27.5%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
VALNValneva SELTM Mar 202683.89M +18.5%+13.4%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
Peer median (excluding VIR) 162.41M+3.0%+4.1%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.